# EDGAR Filing Document

**Accession Number:** 0000001800
**File Stem:** 0001772286-25-000003
**Filing Date:** 2025-12
**Character Count:** 8575
**Document Hash:** 1d7ac7d70cda019a6c4ea2bab70813a6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001772286-25-000003.hdr.sgml**: 20251219

**ACCESSION NUMBER**: 0001772286-25-000003

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251212

**FILED AS OF DATE**: 20251219

**DATE AS OF CHANGE**: 20251219

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Scoggins Christopher J
- **CENTRAL INDEX KEY:** 0001772286

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-02189
- **FILM NUMBER:** 251588114

**MAIL ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABBOTT LABORATORIES
- **CENTRAL INDEX KEY:** 0000001800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 360698440
- **STATE OF INCORPORATION:** IL
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500
- **BUSINESS PHONE:** 2246676100

**MAIL ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500

## Ex-24

EX. 24

**<u>POWER OF ATTORNEY</u>**

The undersigned constitutes and appoints ELIZABETH C. CUSHMAN, JESSICA H. PAIK, and AARON N. RICE, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned's name, place and stead, and in the undersigned's capacity as an officer of Abbott Laboratories, an Illinois corporation (the "Company"), (i) to prepare, sign, and file with the Securities and Exchange Commission ("SEC") any and all forms and documents required under federal securities laws, including Rule 144 of the Securities Act of 1933, as amended, and Section 16(a) of the Securities Exchange Act of 1934, as amended, a Form ID and any other documents necessary to obtain codes, passphrases and passwords necessary to make electronic filings with the SEC, and any other documents in connection therewith, and (ii) to enroll the undersigned and serve as an account administrator for the undersigned's account in the SEC's enhanced Electronic Data Gathering, Analysis, and Retrieval system ("EDGAR Next") and take any action that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned pursuant to the authority granted to such attorney-in-fact as an account administrator for the undersigned's account in EDGAR Next, in each case, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite, necessary or desirable to be done under said Rule 144 and Section 16(a) and pursuant to such attorney-in-fact's and agent's authority as an account administrator for the undersigned's account in EDGAR Next, as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to make filings under Rule 144 and Section 16(a) with respect to the Company or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Date: December 16, 2025

<u>/s/ Christopher J. Scoggins</u>

Signature of Reporting Person

Christopher J. Scoggins

Abbott Laboratories

100 Abbott Park Road

Abbott Park, IL 60064

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Scoggins Christopher J<br><sub>(Last) (First) (Middle)</sub><br>100 ABBOTT PARK ROAD<br><sub>(Street)</sub><br>ABBOTT PARK, IL 60064<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>ABBOTT LABORATORIES [ ABT ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-12-12 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EXECUTIVE VICE PRESIDENT_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common shares without par value | 63621 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Option (right to buy) | <sup>(1)</sup> | 2029-02-21 | Common shares | 51557 | $75.9 | D |  |
| Option (right to buy) | <sup>(1)</sup> | 2029-03-31 | Common shares | 43388 | $79.98 | D |  |
| Option (right to buy) | <sup>(1)</sup> | 2030-02-20 | Common shares | 68578 | $87.72 | D |  |
| Option (right to buy) | <sup>(1)</sup> | 2031-02-18 | Common shares | 63991 | $124.04 | D |  |
| Option (right to buy) | <sup>(1)</sup> | 2032-02-17 | Common shares | 48852 | $117.58 | D |  |
| Option (right to buy) | <sup>(2)</sup> | 2033-02-16 | Common shares | 37483 | $106.24 | D |  |
| Option (right to buy) | <sup>(3)</sup> | 2034-02-20 | Common shares | 31721 | $116.98 | D |  |
| Option (right to buy) | <sup>(4)</sup> | 2035-02-24 | Common shares | 45730 | $135.42 | D |  |

---

### Footnotes:

(1) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

(2) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,494 on February 17, 2024, 12,494 on February 17, 2025, and 12,495 on February 17, 2026.

(3) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,573 on February 21, 2025, 10,574 on February 21, 2026, and 10,574 on February 21, 2027.

(4) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,243 on February 25, 2026, 15,243 on February 25, 2027, and 15,244 on February 25, 2028.

**Signature:** /s/ Christopher J. Scoggins by Jessica H. Paik, Attorney-in-Fact  
**Date:** 2025-12-19

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**